We have 9 different ratings for every stock to help you appreciate its future potential. We’d like to share more about how we work and what drives our day-to-day business. CompareNVRO’s historical performanceagainst its industry peers and the overall market. Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.
game principle ii: dominant strategies Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain.
The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. The company sells its products through its direct sales force, and … EV / Sales ,41x EV / Sales ,96x Nbr of Employees Free-Float 95,5% More FinancialsCompanyNevro Corp. is a global medical device company.
The Company is focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company has developed and commercialized its HFX spinal cord stimulation platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic… At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.52% per year. These returns cover a period from January 1, 1988 through February 6, 2023.
Is It Time to Buy NVRO? Shares are up today.
EnviroGold https://1investing.in/ Ltd. operates as a development stage company. It focuses on investing in entities involved in the acquisition, exploration, and development of extractive industries. The company was founded on March 1, 2005 and is headquartered in Vancouver, Canada.
This stock may move much during the day and with a large prediction interval from the Bollinger Band this stock is considered to be “high risk”. During the last day, the stock moved $0.88 between high and low, or 2.59%. For the last week, the stock has had daily average volatility of 2.84%. Get the hottest stocks to trade every day before the market opens 100% free. Canaccord Genuity gave a rating of “Buy” to NVRO, setting the target price at $67 in the report published on December 20th of the previous year. After moving -22.0% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 84% of the occasions.
Nevro – NVRO Price Target & Analyst Ratings
In addition, it offers surpass surgical and percutaneous leads. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California. 10 brokerages have issued twelve-month target prices for Nevro’s shares. Their NVRO share price forecasts range from $31.00 to $95.00.
NVRO stock returns are also predicted based on historical data. Nevro reported Q4 EPS of ($0.54), $0.05 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $113.84 million versus the consensus estimate of…
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NVRO quote. The average price predicted by analysts for NVRO is $44.50, which is $9.81 above the current price. The public float for NVRO is 34.58M and currently, short sellers hold a 7.79% ratio of that float. The average trading volume of NVRO on April 07, 2023 was 614.12K shares. Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg.
- It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence.
- They are trying to find them, count their potential and bring them to their clients.
- High-growth stocks tend to represent the technology, healthcare, and communications sectors.
- Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Nevro issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $445.00 million-$455.00 million, compared to the consensus revenue estimate of $449.24 million.
The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States. Nevro Corp share price live 35.42, this page displays NYSE NVRO stock exchange data. View the NVRO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nevro Corp real time stock price chart below.
Volatility was left at 3.78%, however, over the last 30 days, the volatility rate increased by 2.76%, as shares surge +9.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.42% lower at present. Piper Sandler, on the other hand, stated in their research note that they expect to see NVRO reach a price target of $38, previously predicting the price at $42. The rating they have provided for NVRO stocks is “Underweight” according to the report published on January 06th, 2023. But now that NVRO stock has fallen a large 22% in a month, will it continue its downward trajectory, or is a rise imminent?
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. This crisis has hit income-seekers—particularly retirees—hard.
They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Nevro witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn’t suggest further strength down the road.